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Abstract
Background: As part of the national seasonal influenza vaccination programme in England and Wales, children receive
a quadrivalent vaccine offering protection against two influenza A strains and two influenza B strains. Healthy children
receive a quadrivalent live attenuated influenza vaccine (QLAIV), whilst children with contraindications receive the
quadrivalent inactivated influenza vaccine (QIIV). Individuals aged younger than 65 years in the clinical risk populations
and elderly individuals aged 65+ years receive either a trivalent inactivated influenza vaccine (TIIV) offering protection
from two A strains and one B strain or the QIIV at the choice of their general practitioner.
The cost-effectiveness of quadrivalent vaccine programmes is an open question. The original analysis that supported
the paediatric programme only considered a trivalent live attenuated vaccine (LAIV). The cost-effectiveness of the QIIV
to other patients has not been established. We sought to estimate the cost-effectiveness of these programmes,
establishing a maximum incremental total cost per dose of quadrivalent vaccines over trivalent vaccines.
Methods: We used the same mathematical model as the analysis that recommended the introduction of the
paediatric influenza vaccination programme. The incremental cost of the quadrivalent vaccine is the additional
cost over that of the existing trivalent vaccine currently in use.
Results: Introducing quadrivalent vaccines can be cost-effective for all targeted groups. However, the cost-effectiveness
of the programme is dependent on the choice of target cohort and the cost of the vaccines: the paediatric programme
is cost-effective with an increased cost of £6.36 per dose, though an extension to clinical risk individuals younger than
65 years old and further to all elderly individuals means the maximum incremental cost is £1.84 and £0.20 per
dose respectively.
Conclusions: Quadrivalent influenza vaccines will bring substantial health benefits, as they are cost-effective in
particular target groups.
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Background
Seasonal influenza is a major public health problem in
England. It is estimated that approximately 10% of all
respiratory hospital admissions and deaths can be attrib-
uted to circulating influenza, with the highest admission
rates for both influenza A and B strains attributed to
children under 5 years of age and the highest influenza-
attributed deaths rates seen in the group of elderly
patients with co-morbidities [1].
Two antigenically and genetically distinct influenza B
lineages emerged in the early 1980s and have since
spread globally, co-circulating every influenza season [2].
An analysis published in 2014 reported that children
younger than 15 years bear the largest burden of disease
due to influenza B strains in England, with 1744 annual
general practitioner (GP) consultations per 100,000 (95%
confidence interval, CI 1656–1832) for those children
aged 5–14 years [1]. However, the burden of GP consulta-
tions attributed to influenza B infection for older members
of the population is not insignificant, with 552 (95% CI
528–576) and 361 (95% CI 340–382) GP consultations per
100,000 per year for individuals aged 15–44 years and 45–
65 years respectively. However, no GP consultations or
hospitalisations for those individuals aged 65 years and* Correspondence: dominic.thorrington@phe.gov.uk1Respiratory Diseases Department, Public Health England, 61 Colindale
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older were attributed to influenza B on average each
season.
In England, seasonal influenza vaccination is offered to
several population groups: elderly individuals aged 65 years
and older; clinical risk groups; and more recently the
Department of Health has started the incremental intro-
duction of the offer of vaccination to healthy children
aged 2–16 years. A cost-effectiveness analysis [3] demon-
strated that a trivalent live attenuated influenza vaccine
(LAIV) offered to this cohort would be very cost-effective
(£1949 per quality-adjusted life year, QALY) and would
bring substantial public health benefits in the form of
reduced health care resource use through both direct
protection to children and indirect protection to both
the clinical risk groups and elderly individuals. The
programme is not being rolled out to all children
aged 2–16 years at once but to incremental age bands
each year in England, with all children aged 2–7 years
offered the vaccine in 2016–2017 [4] with all children
up to age 11 years to be offered vaccination soon. In
2014–2015 the programme was implemented with a
quadrivalent live attenuated influenza vaccine (QLAIV)
for children without contraindications [5, 6], offering
protection against two influenza A strains and two influ-
enza B strains. For all individuals in clinical risk groups
the Joint Committee on Vaccination and Immunisation
(JCVI) recommends the quadrivalent inactivated influenza
vaccines (QIIVs) as being preferable to the trivalent inacti-
vated influenza vaccines (TIIVs) with all other things
being equal [7].
GPs and pharmacists are able to procure QIIVs from
various manufacturers for their adult patients in clinical
risk groups, defined as those with chronic respiratory,
heart, kidney, liver or neurological disease, diabetes,
immunosuppression or asplenia [7] with morbid obesity
added to the list from 2017–2018 [8, 9]. The vaccines
are purchased from manufacturers directly before GPs
and pharmacists are reimbursed. Quadrivalent vaccines
administered to those individuals in clinical risk groups
and to the elderly population may reduce influenza B-
attributed morbidity and mortality, as recent randomised
controlled trials (RCTs) have demonstrated the superiority
of quadrivalent vaccines over trivalent vaccines in both
adults [10] and children [11]. The cost-effectiveness of
dispensing quadrivalent influenza vaccines to clinical risk
groups and the elderly population should be assessed in
light of the successful paediatric seasonal influenza vaccin-
ation programme that will soon include all children
attending primary schools.
This analysis considers the direct and indirect impact of
administering an inactivated quadrivalent seasonal influ-
enza vaccine to those individuals aged < 65 years in clinical
at-risk groups and subsequently to all elderly individuals,
in addition to assessing the impact of the paediatric
programme administering QLAIVs to healthy children
and QIIVs to those children with contraindications com-
pared to the predicted impact of the trivalent vaccines.
We sought to establish the maximum incremental cost
per dose of the quadrivalent vaccines over existing triva-
lent vaccines to all targeted cohorts.
Methods
Modelling approach
We used the same mathematical model as the one in [3]
and [12], used to recommend the introduction of the
paediatric seasonal influenza vaccination programme in
the UK. The model brings together surveillance data from
a variety of primary care, secondary care and sentinel data
sources in addition to data on social contact patterns and
seroepidemiological data and uses these data in a Bayesian
approach, specifically adaptive Markov chain Monte Carlo
(MCMC) techniques, to reconstruct epidemics using a
transmission model for three influenza subtypes over
14 years. The model simulated seasonal influenza out-
breaks in seven age groups (<1 year, 1–4, 5–14, 15–24,
25–44, 45–64 and 65+ years) and two at-risk groups (low
risk, clinical risk). All parameters for both the transmis-
sion model and economic evaluation model remained the
same from both publications. We assumed that the paedi-
atric programme had been implemented for all primary
schools only and simulated epidemics using the model
through the fluEvidenceSynthesis R package [13].
The model follows a modified Susceptible-Exposed-
Infectious-Removed (SEIR)-type structure with gamma-
distributed latent and infectious periods. At the beginning
of an influenza outbreak, a small fraction of individuals in
each age class is infectious with the remainder susceptible
to infection. Mixing between clinical risk groups is ran-
dom within each age group, with the population mixing
patterns described via a resampling of the POLYMOD
matrix for the population of Great Britain [14]. Costs and
health benefits from the perspective of the health care
provider were discounted an annual rate of 3.5%. The full
model and cost-effectiveness framework are described in
greater detail in both [3] and [12].
We simulated four scenarios in the model, described
below and shown in Fig. 1.
Baseline
The baseline scenario is as follows:
 Low-risk young and primary school children (aged
2–11 years) receive the trivalent LAIV, which offers
protection from two influenza A strains and one
influenza B strain.
 Clinical risk and elderly individuals receive the
inactivated trivalent vaccine, offering protection
from two influenza A strains and one influenza B
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strain. This simulates the initial cost-effectiveness
analysis described in [3], though with the paediatric
vaccination programme rolled out to only the
primary schools. All healthy children are eligible for
the seasonal influenza vaccine and they receive the
trivalent LAIV, whilst clinical risk and elderly
individuals continue to receive the inactivated
trivalent vaccine.
Programme 1
Under programme 1, low-risk children without contrain-
dications aged 2–11 years receive the QLAIV, which offers
protection from two influenza A strains and two influenza
B strains. Children with contraindications receive the
QIIV. This modelling scenario depicts the current
seasonal influenza vaccination programme.
Programme 2
Under programme 2, low-risk children aged 2–11 years
and the clinical risk individuals aged < 65 years receive a
quadrivalent vaccine (QLAIV for low-risk children, QIIV
for contraindicated children and clinical risk individuals
< 65 years). This modification to the current programme
sees protection against an additional strain offered to clin-
ical risk individuals aged < 65 years, with the additional
cost of the QIIV paid in reimbursements to GPs and phar-
macists who administer the vaccine to persons < 65 years
old in their surgeries.
Programme 3
Under programme 3, low-risk children aged 2–11 years
and clinical risk individuals of all ages in addition to all
individuals aged 65 years and older receive a quadri-
valent vaccine, ensuring that all eligible individuals in
England are offered a quadrivalent vaccine (QLAIV
for low-risk children without contraindications and
QIIV for all other eligible individuals).
Finally, we simulated all four scenarios again with the
addition of a paediatric vaccination programme that had
been fully rolled out to include all children aged 2–16
years.
Model parameters
No efficacy studies have been published on the QIIV [15].
The efficacy of the QLAIV used in low-risk children has
not yet been demonstrated in clinical trials. The manufac-
turers of the inactivated vaccine also manufacture two tri-
valent influenza vaccines formulated with the same two
influenza A strains (both A/H1N1 and A/H3N2) but
different B strains (Victoria lineage and Yamagata lineage
respectively). The efficacies of these vaccines are consid-
ered to be good predictors of the efficacy of the QIIV, as
the manufacturing process for all strains was unchanged
from that of the trivalent vaccines [16]. We therefore
assumed equivalent efficacy for the QIIV, where the
trivalent vaccine was poorly matched to the circulating
influenza B strains and the quadrivalent vaccine was
well matched, using the same parameters from [12] and
[3] listed in Table 1.
Vaccination coverage data for all age and risk groups
were taken from the monthly coverage data published by
Public Health England [17]. The data for the final cover-
age achieved are shown in Table 1. The primary and
tertiary care costs from [3] were updated.
Fig. 1 Scenarios simulated in the model
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We assumed that the new quadrivalent vaccine adminis-
tered to the clinical risk groups and elderly individuals
would cost the same per dose as the quadrivalent vaccine
administered to school children. The maximum incre-
mental cost per dose of the quadrivalent vaccines over the
trivalent vaccines was estimated using a threshold analysis
on the mean incremental cost-effectiveness ratios for each
proposed vaccination programme for a series of potential
willingness-to-pay (WTP) thresholds. The incremental
vaccine costs were varied from no difference to £15.
The criteria to be cost-effective were in line with rec-
ommendations from the JCVI that 90% of simulations
had an incremental cost-effectiveness ratio below the
WTP threshold [18].
Epidemics for each vaccination programme were simu-
lated 1000 times. We estimated the mean savings in
primary care and tertiary care, reporting 95% CIs of the
means based on 1000 bootstrap replications.
Sensitivity analysis
We conducted a sensitivity analysis using the highlighted
parameters (indicated with §) in Table 1 to assess the
sensitivity of our estimates to parameter uncertainty.
The efficacy of the quadrivalent vaccines in preventing
infection from influenza B is unclear, so we assumed a
variation of ±20% in absolute terms. The uptake for all
three target cohorts was varied by ±10% in absolute
terms. In addition, we varied the proportion of infections
that attend primary care consultations with influenza-
like illness (ILI) symptoms by ±50% of that reported in
[1]. The impact of these uncertainties was assessed
against the most cost-effective incremental cost of the
quadrivalent vaccines with a WTP threshold of £20,000
per QALY.
Results
Figure 2 shows the variation in the distribution of ILI
cases across the modelled scenarios. Using the trivalent
LAIV for low-risk school children as well as a trivalent
inactivated vaccine in all other eligible groups resulted in
approximately 1,819,711 infections (95% CI 1,807,163–
1,831,307). The introduction of the QLAIV to low-risk
school children without contraindications alongside the
QIIV for those children with contraindications reduced
the case burden caused by ILI infection by 35% to
1,176,059 (95% CI 1,163,850–1,189,061). Simulating the
introduction of the quadrivalent inactivated vaccine to
clinical risk individuals under 65 years old reduced the
case burden to 1,039,774 (95% CI 1,028,029–1,051,566),
and the addition of those individuals aged 65 years and
older further reduced the case burden to 1,000,477
(95% CI 989,314–1,011,567). A full breakdown of the
estimated incremental benefits of each proposed vac-
cination programme is presented in Table 2.
Table 1 Parameters used in the dynamic transmission model
Parameter Value and uncertainty Source
Efficacy against B strain(s)
TIIV and LAIV, < 65 years 42% [3]
TIIV and LAIV, 65+ years 28% [3]
QIIV and QLAIV, < 65 years § 70% (min. 50%, max. 90%) [3]
QIIV and QLAIV, 65+ years § 46% (min. 30%, max. 70%) [3]
Influenza vaccination coverage
Low-risk < 5 years § 33.7% (±10%) [17]
Low-risk 5–16 years § 54.9% (±10%) [17]
Clinical risk < 6 months–
64 years §
45.1% (±10%) [17]
65+ years § 71.0% (±10%) [17]
Health care resource costs
GP consultation £46, lognormal (mean 46,
standard deviation 8.4)
[3]
Inpatient admission £1050, lognormal (mean 1050,
standard deviation 192.1)
[3]
The § symbol denotes that the parameter was used in the sensitivity analysis
Fig. 2 Distribution of the number of infections for each vaccination scenario
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If the WTP threshold is £20,000 per QALY, then the
maximum incremental cost of the quadrivalent vaccine
for school children is £6.36. Further extension to clinical
risk individuals younger than 65 years old and to all in-
dividuals aged 65+ years resulted in maximum incre-
mental costs of £1.84 and £0.20 respectively. Increasing
the WTP threshold to £30,000 per QALY means that
each of the three proposed vaccination programmes
would be cost-effective with maximum incremental costs
of £8.89, £2.66 and £0.31 respectively.
The maximum incremental cost of the quadrivalent
vaccines that ensures a cost-effective programme for all
targeted cohorts is very small because of the projected
health care resource use of the elderly population
infected with influenza B. Extending a quadrivalent vac-
cination programme to all clinical risk and elderly indi-
viduals reduces the number of febrile influenza B cases
by 16,218 with projected savings in primary and sec-
ondary care, but at the increased cost of vaccinating
nearly 9,000,000 individuals of whom 74% are aged
65 years or older and less likely to require primary or
secondary care intervention.
Additional results assuming all children aged 2–16 years
are eligible
If the paediatric vaccination programme is extended to all
children of ages 2–16 years, then the maximum incremen-
tal costs of the quadrivalent vaccines in each proposed
programme would be £4.04, £1.03 and £0.06 respectively.
Model sensitivity
It is clear from the results presented in Table 3 that the
programme that allows the largest variation in costs be-
tween the trivalent and quadrivalent vaccines is the paedi-
atric programme. The cost-effectiveness of this programme
is most sensitive to the efficacy of the paediatric QLAIV/
QIIV to the B strains. If the vaccine used for children was
more efficacious at preventing influenza B infection, then
the maximum incremental cost of the vaccine would be
£9.01, whilst a less efficacious vaccine would need to be
£2.42 more expensive than the paediatric LAIV/TIIV to
remain cost-effective (Fig. 3). Variation in the uptake of the
vaccine in this age group by ±10% in absolute terms is also
a source of uncertainty for the maximum incremental cost
of the QLAIV. In comparison, the rate of GP consulta-
tions attributable to ILI had little impact on the cost-
effectiveness of the programmes as did the uptake of
trivalent vaccines in the older age groups.
Other parameters such as the efficacy of the QIIV for
the adult age groups cannot have an impact on the cost-
effectiveness of the paediatric programme. Their impact
on the cost-effectiveness of the adult QIIV programmes
is explored in Additional file 1.
Discussion
We found that the introduction of quadrivalent influenza
vaccines to the seasonal influenza vaccination programme
in England can be cost-effective for all targeted cohorts,
though the cost-effectiveness of the programme imple-
mented is highly dependent on the increased cost of
replacing trivalent vaccines with their quadrivalent
counterparts. Increasing the eligibility for quadrivalent
vaccination programmes further than just the paediat-
ric programme reduces the additional amount that
the National Health Service (NHS) should pay to procure
each vaccine dose. Indeed, if only trivalent vaccines were
available for individuals aged 17 years and younger, then
the maximum incremental cost per dose of QIIV vaccines
for high-risk and elderly individuals would increase to
£3.55 and £0.29 respectively. This increases further to a
minimum of £3.76 and £0.41 respectively if no paediatric
influenza vaccination programme had been implemented
at all, but these latter estimates are likely to be underesti-
mates, as they ignore the substantial change in the
population-wide burden of influenza A attributable to the
LAIV/TIIV paediatric programme [5, 19].
Table 2 Mean incremental benefits of each proposed vaccination programme
Parameter Mean reduction after starting
programme 1
(standard deviation)
Mean reduction after starting
programme 2
(standard deviation)
Mean reduction after starting
programme 3
(standard deviation)
Infections 643,652 (110,710) 136,284 (21,246) 39,297 (16,105)
Symptomatic/febrile cases 59,457 (20,816) 12,578 (4264) 3641 (1942)
GP consultations 63,276 (10,680) 11,305 (1757) 2658 (1123)
Hospitalisations 356 (64) 49 (9) 14 (6)
Table 3 The maximum incremental vaccine cost to ensure that
90% of all simulations are cost-effective to five different WTP
thresholds
Cost per QALY Programme 1 Programme 2 Programme 3
£10,000 £3.69 £1.03 £0.11
£15,000 £5.04 £1.44 £0.16
£20,000 £6.36 £1.84 £0.20
£25,000 £7.58 £2.25 £0.26
£30,000 £8.89 £2.66 £0.31
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The maximum incremental cost per dose of the
quadrivalent vaccine for high-risk and elderly individuals
reduces further from £1.84 and £0.20 if the paediatric
influenza vaccination programme is ultimately imple-
mented for all age groups in schools as planned. This is
due to two factors: first the heterogeneous burden of influ-
enza B in the population is concentrated in the younger
age groups, so a vaccination programme that targets all
children of ages 2–16 years will reduce a large proportion
of this total burden. Second, the well-demonstrated indir-
ect effect of vaccinating children to protect other age
groups reduces the potential impact of any vaccination
programme in the remaining population, thereby reducing
the amount that should be spent on those vaccination pro-
grammes after a successfully implemented paediatric
programme. Any additional resources required to imple-
ment the paediatric influenza vaccination programme
would be the same whether the programme used a triva-
lent or quadrivalent live attenuated vaccine, so we did not
consider this potential additional cost in our analysis.
Strengths and weaknesses of this study
This study uses a dynamic transmission model that was
fitted to 14 years of surveillance data, and it uses the same
cost-effectiveness framework that was used to support the
decision to implement a nationwide seasonal influenza
vaccination programme for healthy children [12], provid-
ing a consistent approach to understanding the impact of
an evolving vaccination programme. This approach, as
outlined in the previous publications, accounts not just
for the direct protection inferred on vaccinated individuals
but also the indirect protection inferred on unvaccinated
individuals in the population. The model also uses the
same data [14] on social contacts to account for mixing
patterns in the population, an important inclusion to
understanding infectious disease dynamics [20].
We assumed that existing trivalent vaccines were
poorly matched to the dominant circulating B strain in
each influenza season. Whilst this assumption allowed
us to maintain a consistent modelling approach with
that of Baguelin et al., we recognise that it presents the
best-case scenario for introducing quadrivalent vaccines.
In addition, other countries have reported that some
vaccines were well matched against the dominant circu-
lating influenza B strains with little activity for the
unmatched B strain [21, 22], which would reduce the
maximum incremental cost per dose of quadrivalent
vaccines in our analysis. However, our approach allows
us to report the maximum incremental cost in the best
possible scenario for quadrivalent vaccines with the un-
derstanding that any previous years with a better strain
match in vaccines will reduce the cost-effectiveness of
quadrivalent vaccines. Indeed, the estimated proportion
of influenza B infections between 2000 and 2010 caused
by vaccine mismatched strains was 52.4% [23], present-
ing an encouraging opportunity for quadrivalent vac-
cines to reduce the public health impact of seasonal
influenza.
We did not consider extending eligibility to children
aged younger than 2 years old, in contrast to paediatric
vaccination programmes in some other countries. The
live attenuated vaccine is not licensed for children in this
age group; and the effectiveness of inactivated vaccines
is lower [24]; and implementation of a programme using
an injectable vaccine would represent a considerable
additional workload for a policy that has not been
recommended in the UK.
Our economic evaluation of the vaccination pro-
grammes followed the guidelines recommended by the
National Institute for Health and Clinical Excellence
(NICE) in evaluating the costs of the programme from the
perspective of the health care provider [25]. We took a
conservative approach in assessing the potential additional
expenditure appropriate to reducing the disease burden
caused by influenza B strains. We considered vaccination
programmes with at least 90% of all simulations below the
Fig. 3 Tornado plot showing the estimated change in the maximum incremental cost per dose of the quadrivalent vaccines for programme 1,
assuming a WTP threshold of £20,000 per QALY
Thorrington et al. BMC Medicine  (2017) 15:166 Page 6 of 9
WTP threshold as cost-effective, with a WTP threshold of
£20,000 per QALY as recommended by NICE. We also
reported our results for other WTP thresholds should that
advice change in the future.
Our sensitivity analysis reported that our model esti-
mates are most sensitive to the estimated efficacy of the
QLAIV in preventing influenza B infection, but the
manufacturers of the vaccine have not confirmed these
estimates and have instead hypothesised that the simi-
larity in manufacturing processes between the LAIV
and QLAIV implies that there is no difference. Greater
clarity on the estimated efficacy of the QLAIV in pre-
venting influenza B infection would greatly improve the
accuracy of our estimates.
A recent systematic review of economic evaluations
assessing the impact of quadrivalent influenza vaccines
compared the modelling approaches and results of 16 ana-
lyses published before September 2016 [26]. The authors
reported that 13 of these analyses were funded by vaccine
manufacturers, two did not specify the funding source
and the one remaining study was publicly funded. Our in-
dependent study is therefore a helpful addition to the
literature on the cost-effectiveness of quadrivalent vac-
cines that is so dominated by industry-funded studies. In
addition, the review of de Boer et al. calls for more exten-
sive use of dynamic transmission models to fully under-
stand the impact of quadrivalent vaccines in influenza
vaccination programmes, an approach that we adopted
here using the fluEvidenceSynthesis R package.
Relation of this study to other studies
The review of de Boer et al. reported that the range of
incremental cost per dose of quadrivalent vaccines over
existing trivalent equivalents for all studies was $1.25 to
$7.14 in 2015 US dollars [26], though there was variation
in the perspective for which economic evaluations were
performed, the WTP thresholds for each country and
the requirement of the proportion of simulations that
should be below those WTP thresholds. Many studies
reported that quadrivalent vaccines are cost-effective
with an emphasis of the sensitivity of these estimates to
the parameters for the cost of vaccines and the efficacy
of vaccines considered against the circulating influenza
B strains. We adopted a conservative approach to our
economic evaluation and feel that our conservative in-
cremental cost-per-dose estimates for each proposed
programme compare well to those of the studies
featured in this review, with similar findings from our
sensitivity analysis to those featured in the review.
Possible explanations and implications for clinicians and
policymakers
Extending a QIIV programme to include clinical risk
individuals younger than 65 years old in England is more
likely to be cost-effective than extending further to also
include all elderly individuals. However, the maximum
incremental cost per dose of the quadrivalent vaccines is
just £1.84, meaning that the current policy of reimburs-
ing GPs and pharmacists for administering QIIVs to
clinical risk groups is likely to be cost-effective if the in-
cremental reimbursement cost is less than this value and
less than £0.20 per dose if extended further to all elderly
individuals. This result is influenced by the heteroge-
neous burden of influenza B infection in England [1],
with children shouldering the largest proportion of this
burden; therefore, directly protecting the elderly from
infection with QIIV offers a smaller return than the
QLAIV programme in schools.
Unanswered questions and future research
We did not address the issue of adverse events arising
from vaccination using the QIIV and QLAIV and assumed
that these risks were negligible, as clinical trials suggest
that the quadrivalent vaccines have similar safety profiles
to those of the trivalent vaccines [11, 27, 28]. We did not
consider the implications of infection from natural expos-
ure to influenza B, nor did we attempt to estimate the im-
pact of repeated vaccination on the immunogenic
response in the patient.
Conclusions
According to our analysis, the introduction of the
QLAIV to healthy children is likely to be cost-effective
if the quadrivalent vaccine costs no more than £6.36
more than the trivalent live attenuated vaccine that was
introduced in 2012. Given the projected reduction in
the population-wide burden of influenza B, the intro-
duction of quadrivalent influenza vaccines to the sea-
sonal influenza vaccination programme for clinical risk
groups and particularly elderly individuals is likely to
be cost-effective only in narrow circumstances. The
cost to reimburse GPs and pharmacists administering
the QIIV to clinical risk groups needs to be evaluated
in light of these findings.
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